Skip to main content
Contact Us
Subscribe
E-Edition
70°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gb Sciences Inc
(OP:
GBLX
)
0.0072
+0.0001 (+1.41%)
Streaming Delayed Price
Updated: 3:05 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gb Sciences Inc
< Previous
1
2
Next >
GB Sciences Signs Letter of Intent for a License to Develop and Market Their Cannabinoid-Based Parkinson’s Formulation With Endopure Life Sciences
July 02, 2024
Via
ACCESSWIRE
Gb Sciences’ Novel Parkinson’s Disease Medication is Featured on Worldwide Business with kathy ireland(R)
December 14, 2023
Via
ACCESSWIRE
Gb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study at the University of Lethbridge
July 11, 2023
Via
ACCESSWIRE
GB Sciences' First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease Has Been Issued in China
March 20, 2023
Via
ACCESSWIRE
Successful 2022 Milestones Support Value of Gb Sciences' AI-Enabled Drug Discovery Platform
March 07, 2023
Via
ACCESSWIRE
Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform
December 22, 2022
Gb Sciences' innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections.
Via
Newswire.com
Topics
Death
Exposures
COVID-19
Death
Marijuana And Chronic Pain: Gb Sciences' Nanoparticle Technology Boosts Efficacy Of Cannabis Terpenes
March 29, 2022
Gb Sciences, Inc.
Via
Benzinga
Not So Fast With The Cannabis-COVID Treatment: Gb Sciences And Michigan State U Researchers Clarify
February 01, 2022
Following the promising study on cannabinoids and COVID-19 published by Oregon State University, Gb Sciences, Inc.
Via
Benzinga
Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform
December 22, 2022
Gb Sciences' innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections.
From
Gb Sciences
Via
GlobeNewswire
Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations
December 12, 2022
As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging...
Via
Newswire.com
Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations
December 12, 2022
As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging...
From
Gb Sciences
Via
GlobeNewswire
Cannabis Terpenes Reduce Inflammation, Says Gb Sciences Study
November 01, 2022
Gb Sciences, Inc. (OTCQB: GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, co-published a study that demonstrates the potential of selected cannabinoids and...
Via
Benzinga
Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients
November 01, 2022
As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm's sponsored research used co-cultured human, primary immune cells as a model to evaluate the...
Via
Newswire.com
Topics
Cannabis
Exposures
Cannabis
Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study
October 24, 2022
Gb Sciences' anxiety formulations were previously identified using the company's AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the...
Via
Newswire.com
TODAY: Gb Sciences' President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference
October 13, 2022
Dr. Andrea Small-Howard discusses the company's novel process for developing disease-specific, cannabinoid-based therapeutics.
Via
Newswire.com
Topics
Cannabis
Exposures
Cannabis
New Study Shows Promising Results In Treatment Of Parkinson's Disease With Cannabinoids
October 10, 2022
Biopharmaceutical research and drug development company, Gb Sciences, Inc. (OTCQB: GBLX), co-published a study in the journal Frontiers in Pharmacology that demonstrates the efficacy of its proprietary...
Via
Benzinga
Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease
October 10, 2022
As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM)...
Via
Newswire.com
Topics
Cannabis
Exposures
Cannabis
TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article
September 06, 2022
Gb Sciences is focusing considerable resources on bringing its lead Parkinson's disease formulations to the clinic with promising results; plus, new data validating the efficacy of their novel anxiety...
Via
Newswire.com
Topics
Cannabis
Exposures
Cannabis
TODAY: Gb Sciences' President and Chief Science Officer Presents Keynote Address on Cannabinoid-Containing Formulations for Parkinson's Disease at 2022 NeuroForum Summit
May 23, 2022
Dr. Andrea Small-Howard explains that Gb Sciences' multicomponent Parkinson's disease therapeutic addresses this multi-factorial neurodegenerative condition using a combination of cannabinoids that are...
Via
Newswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit
May 12, 2022
President and Chief Science Officer Dr. Andrea Small-Howard demonstrates the platform's utility for predicting novel plant-inspired drug candidates and describes its role in Gb Sciences' future...
Via
Newswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference
May 05, 2022
President and Chief Science Officer Dr. Andrea Small-Howard stressed the importance of developing their innovative, plant-inspired formulations as a potentially safer alternative to existing...
Via
Newswire.com
FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences' COVID-19-Related, Anti-Inflammatory Therapies
May 02, 2022
Plant-inspired biopharmaceutical company signs leading contract research organization to help with a go-to-market strategy for its cannabinoid-containing therapy for COVID-related cytokine release...
Via
Newswire.com
Exposures
COVID-19
Gb Sciences To Begin Dosage Study For Cannabinoid-Containing Drug For Treatment Of Parkinson's Disease
April 12, 2022
Gb Sciences, Inc. (OTCQB: GBLX) has selected the University of Lethbridge in Canada to complete a dose range study of Gb Sciences' patent-protected formulations in a rodent model of Parkinson's...
Via
Benzinga
Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge
April 12, 2022
Biopharmaceutical research company's plant-inspired formulations entering final stages before first-in-human clinical trials
Via
Newswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Our Chronic Pain Formulations as Demonstrated in New Research Article
March 29, 2022
On March 25, the University of Seville, Chaminade University, and Gb Sciences co-published the results from Gb Sciences-sponsored study in the International Journal of Pharmaceutics. Gb Sciences'...
Via
Newswire.com
UPDATE: Gb Sciences Issues Shareholder Letter
March 16, 2022
Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021
Via
Newswire.com
Gb Sciences Issues Summary Shareholder Letter
March 15, 2022
Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021
Via
Newswire.com
Gb Sciences Issues Shareholder Letter
March 15, 2022
Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021
Via
Newswire.com
Gb Sciences Granted U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis
March 01, 2022
This new patent covers receptor-targeted formulations for the treatment of cardiac hypertrophy, TRPV1-receptor-associated hearing loss and urinary cystitis.
Via
Newswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
Gb Sciences and Michigan State University Researchers Have Identified the Complicated Truth Behind the Opportunity for an Effective Cannabinoid-Based Coronavirus Treatment
February 01, 2022
Gb Sciences' collaboration with MSU has received media coverage across the country, starting with an interview from WLNS-TV in Lansing, Michigan, and interviews with Gb Sciences in the magazines...
Via
Newswire.com
Topics
Cannabis
Exposures
COVID-19
Cannabis
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.